Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
BiomX Inc. Announces 1-for-10 Reverse Stock Split
06:30am, Thursday, 15'th Aug 2024
GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapie
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
07:00am, Thursday, 08'th Aug 2024
GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapie
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
07:00am, Monday, 29'th Jul 2024
GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapie
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
06:30am, Wednesday, 10'th Jul 2024
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapie
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
04:50pm, Thursday, 30'th May 2024
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and eng
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
07:00am, Thursday, 30'th May 2024
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and eng
BiomX (PHGE) Q1 2024 Earnings Call Transcript
10:25am, Tuesday, 21'st May 2024
BiomX Inc. (NYSE:PHGE ) Q1 2024 Earnings Conference Call May 21, 2024 8:00 AM ET Company Participants Jonathan Solomon - Chief Executive Officer Avi Gabay - Chief Financial Officer Conference Call Par
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
06:30am, Tuesday, 21'st May 2024
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
07:00am, Wednesday, 15'th May 2024
GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural an
Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024 Abstract selected as a “Top Poster”, ranking it amon
BiomX Announces the Appointment of Susan Blum to its Board of Directors
08:00am, Thursday, 18'th Apr 2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and en
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
10:56am, Friday, 05'th Apr 2024
BiomX (PHGE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Str
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
07:49am, Thursday, 04'th Apr 2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therap
BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript
12:26pm, Wednesday, 03'rd Apr 2024
BiomX Inc. (NYSE:PHGE ) Q4 2023 Earnings Conference Call April 3, 2024 8:00 AM ET Company Participants Avi Gabay - Interim CFO Jonathan Solomon - CEO Conference Call Participants Joseph Pantginis - H.
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
06:30am, Wednesday, 03'rd Apr 2024
Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline
